As mentioned above and shown in Figure 3, it was difficult to find a significant association of TMB, TNB, MSI, HLA-LOH (loss of heterozygosity in human leukocyte antigens), PD-L1 expression, and sarcoma types with the clinical response of anti-PD-1-based therapy in our cohort. This evidence concerns the gene CD274 and sarcoma.